Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-27T03:41:49.271Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuroleptics and cancer

Published online by Cambridge University Press:  16 April 2020

G.J. Gómez-Bernal ,
A. Reboreda ,
M. Bernal ,
F. Romero  and
E. Esteban
G.J. Gómez-Bernal
Affiliation:
Hospital Psiquiátrico de Teruel, Spain
A. Reboreda
Affiliation:
Hospital Psiquiátrico de Teruel, Spain
M. Bernal
Affiliation:
Universidad de Zaragoza, Zaragoza, Spain
F. Romero
Affiliation:
Hospital Psiquiátrico de Teruel, Spain
E. Esteban
Affiliation:
Hospital Psiquiátrico de Teruel, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and aims:

There are some indications in the literature that the use of dopamine antagonists can modify the risk of developing different types of neoplasms.

Methods:

We have reviewed last studies which have reported the possible relationship between cancer and neuroleptic treatment.

Results and Conclusions:

Antipsychotics which increase the level of prolactin, could possible increase the risk of developing breast and endometrial cancer in patients with schizophrenia. Other studies, shows a marked apoptotic effect of phenothiazines in brain-derived cancer cells.

Type
Poster Session 1: Antipsychotic Medications
Information
European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S154
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.